H2R Thursday, 10/26/17 03:18:42 PM Re: None Post # of 1503 New SA article on CYTK https://seekingalpha.com/article/4116891-cytokinetics-separating-wheat-chaff Quote:Biotech investors bear the dual risk of -drug approval and -drug market acceptance. In my opinion, the market risk for Tirasemtiv if approved, is essentially nil. The sales force needed to commercialize the ALS drug need to only be extremely small. It's not a stretch to say that a single rep with a telephone could sell the drug to the majority of ALS treatment providers and patients in the US. So if approved, we should have a big time winner!